Fisher & Paykel share price slides hard following FY23 guidance update

The company reaffirmed its posture to the market today.

| More on:
Man going down a red arrow, symbolising a sliding share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Fisher & Paykel posted its guidance for the first half of FY23 
  • Investors have sold off shares en masse following the update 
  • In the past 12 months, the Fisher & Paykel share price is down 44% 

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price is struggling from the open on Friday following a company update.

At the time of writing, the Fisher & Paykel share price is trading 6% down at $17.98 after it announced its FY23 guidance.

Fisher & Paykel expects slow down in FY23

Detailing its forecasts for the coming 12 months, the healthcare giant said that it anticipates revenue of $670 million and net profit after tax (NPAT) of $85–$95 million.

This signifies an increase in revenue compared to 1H FY20's $570.9 million yet a decline in revenue compared to the prior comparable period, being 1H FY22 at $900 million.

CEO Lewis Gradon said the company had "sold approximately ten years' worth of hardware in two years" creating a high comparison in FY22 as well.

"This does not change the fundamentals of our business or our strategy," he added.

"Our Hospital sales teams are still focused on changing clinical practice and helping ensure the hardware our customers have purchased is used to benefit a broader range of patients requiring respiratory support."

Gross margin for the first half is also expected to land at 60% – 500 basis points below the company's long-term target of 65%.

Part of the contraction in gross profit is due to a shift in sales towards the lower margin consumables segment.

However, despite challenges, it expects that H2 FY23 revenue will be higher than the first half as hospitalisation rates normalize.

"The company is now targeting constant currency operating expense growth of approximately 10%
for the year," it added.

Never before in our history have we changed clinical practice with such a significant advantage.
Our customers already have our hardware, they already have clinical experience with its use, and
they already have access to a huge amount of clinical evidence. This gives us confidence that we
can continue to build on our proven 50-year track record and reach more patients with our
respiratory therapies.

In the past 12 months, the Fisher & Paykel share price is down 44%, and down 41% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Mergers & Acquisitions

Own Sigma shares? Here's the latest on the Chemist Warehouse merger

One year ago today, the two companies announced plans to merge. We could now be just a few months away…

Read more »